Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Outline the efficacy, safety, selectivity, and clinical trial data of JAK inhibitors

Faculty

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California

Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Outline the efficacy, safety, selectivity, and clinical trial data of JAK inhibitors

Faculty

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California

Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Employ strategies to assist patients in overcoming access barriers to effective RA therapies

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas

Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Madelaine A. Feldman, MD, FACR
President, Coalition of State Rheumatology Organizations
Chair, Alliance for Safe Biologic Medicines
Clinical Assistant Professor of Medicine
Tulane University School of Medicine
The Rheumatology Group
New Orleans, Louisiana

Dr. Madelaine Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is President of the Coalition of State Rheumatology Organizations, Chair of the Alliance for Safe Biologic Medicines, and past member of the American College of Rheumatology insurance subcommittee.

A Clinical Assistant Professor of Medicine at Tulane University School of Medicine in New Orleans, Louisiana, she has testified before the Energy and Commerce Subcommittee on Health regarding transparency in drug pricing and the drug supply chain (specifically pharmacy benefit managers [PBMs), and several state legislative committees on PBMs and transparency.

Dr. Feldman received the Distinguished Service Award from Tulane Medical School and was named one of the Top Women in New Orleans by City Business in 2017.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California

Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Madelaine A. Feldman, MD, FACR
Consultant/Independent Contractor: Bristol Myers Squibb Company, Gilead Sciences, Inc.
Speakers Bureau: Eli Lilly and Company.
Stock Shareholder: Celgene Corporation.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Employ strategies to assist patients in overcoming access barriers to effective RA therapies

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas

Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Madelaine A. Feldman, MD, FACR
President, Coalition of State Rheumatology Organizations
Chair, Alliance for Safe Biologic Medicines
Clinical Assistant Professor of Medicine
Tulane University School of Medicine
The Rheumatology Group
New Orleans, Louisiana

Dr. Madelaine Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is President of the Coalition of State Rheumatology Organizations, Chair of the Alliance for Safe Biologic Medicines, and past member of the American College of Rheumatology insurance subcommittee.

A Clinical Assistant Professor of Medicine at Tulane University School of Medicine in New Orleans, Louisiana, she has testified before the Energy and Commerce Subcommittee on Health regarding transparency in drug pricing and the drug supply chain (specifically pharmacy benefit managers [PBMs), and several state legislative committees on PBMs and transparency.

Dr. Feldman received the Distinguished Service Award from Tulane Medical School and was named one of the Top Women in New Orleans by City Business in 2017.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California

Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Madelaine A. Feldman, MD, FACR
Consultant/Independent Contractor: Bristol Myers Squibb Company, Gilead Sciences, Inc.
Speakers Bureau: Eli Lilly and Company.
Stock Shareholder: Celgene Corporation.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

• Describe recent developments in the understanding of pain pathways/pain pathophysiology
• Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
• Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
• Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA

• Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.

Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA

• Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.

Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA

• Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

• Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

• Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity
• Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

• Describe recent developments in the understanding of pain pathways/pain pathophysiology
• Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
• Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
• Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA

• Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.

Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA

• Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.

Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA

• Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

• Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

• Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity
• Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
  • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Utilize appropriate biomarker testing to identify patients with early inflammatory disease.
• Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.

Activity Description

In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of rheumatoid arthritis (RA).

Faculty

Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB

Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer

John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Utilize appropriate biomarker testing to identify patients with early inflammatory disease.
• Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.

Activity Description

In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of rheumatoid arthritis (RA).

Faculty

Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB

Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer

John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com